PAM
LGND icon

Panagora Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Panagora Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-465
Closed -$28K – 2872
2020
Q3 		$28K Sell
465
-3,244
-87% -$221K ﹤0.01% 2130
2020
Q2 		$259K Buy
3,709
+465
+14% +$29.5K ﹤0.01% 1439
2020
Q1 		$146K Sell
3,244
-11,760
-78% -$667K ﹤0.01% 1557
2019
Q4 		$976K Sell
15,004
-22,559
-60% -$1.51M ﹤0.01% 1063
2019
Q3 		$2.33M Sell
37,563
-13,996
-27% -$879K 0.01% 684
2019
Q2 		$3.67M Sell
51,559
-184,024
-78% -$13.6M 0.02% 594
2019
Q1 		$18.5M Buy
235,583
+36,058
+18% +$2.73M 0.08% 244
2018
Q4 		$16.9M Buy
199,525
+716
+0.4% +$76.3K 0.08% 230
2018
Q3 		$34M Sell
198,809
-6,474
-3% -$976K 0.13% 164
2018
Q2 		$26.5M Buy
205,283
+8,314
+4% +$928K 0.11% 190
2018
Q1 		$20.3M Buy
196,969
+698
+0.4% +$69K 0.08% 222
2017
Q4 		$16.8M Sell
196,271
-9,690
-5% -$840K 0.06% 277
2017
Q3 		$17.5M Sell
205,961
-3,112
-1% -$246K 0.07% 273
2017
Q2 		$15.8M Sell
209,073
-104
-0% -$7.28K 0.06% 296
2017
Q1 		$13.8M Sell
209,177
-19,670
-9% -$1.29M 0.06% 333
2016
Q4 		$14.5M Sell
228,847
-725
-0.3% -$45.8K 0.07% 297
2016
Q3 		$14.6M Sell
229,572
-71,018
-24% -$5.21M 0.07% 278
2016
Q2 		$22.4M Sell
300,590
-15,635
-5% -$1.16M 0.11% 187
2016
Q1 		$21.1M Sell
316,225
-2,126
-0.7% -$129K 0.1% 205
2015
Q4 		$21.5M Buy
318,351
+11,647
+4% +$719K 0.11% 202
2015
Q3 		$16.4M Buy
306,704
+35,598
+13% +$2.16M 0.09% 248
2015
Q2 		$17.1M Sell
271,106
-5,339
-2% -$291K 0.09% 252
2015
Q1 		$13.3M Buy
276,445
+20,003
+8% +$766K 0.07% 285
2014
Q4 		$8.51M Buy
256,442
+10,061
+4% +$327K 0.04% 356
2014
Q3 		$7.22M Sell
246,381
-110,032
-31% -$3.65M 0.04% 399
2014
Q2 		$13.8M Sell
356,413
-79,879
-18% -$3.24M 0.07% 273
2014
Q1 		$18.3M Buy
436,292
+41,262
+10% +$1.72M 0.09% 230
2013
Q4 		$13M Buy
395,030
+117,395
+42% +$3.82M 0.06% 303
2013
Q3 		$7.5M Sell
277,635
-18,455
-6% -$519K 0.04% 408
2013
Q2 		$6.91M Buy
+296,090
New +$5.33M 0.04% 378

Other funds holding LGND

William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Panagora Asset Management's LGND Position: Q4 2020 in Review

Panagora Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2020, closing a stake of 465 shares — an estimated $28K sold.

Panagora Asset Management first reported a position in LGND in Q2 2013 and held it in 30 quarters. The position peaked at $34M in Q3 2018. 242 funds tracked by Wall St. Rank hold LGND as of Q4 2020.

  • Panagora Asset Management reported no remaining Ligand Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Panagora Asset Management sold 465 Ligand Pharmaceuticals shares in Q4 2020, an estimated $28K.
  • Panagora Asset Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 30 quarters.
  • Panagora Asset Management's Ligand Pharmaceuticals position peaked at $34M in Q3 2018.
  • 242 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2020.

Based on Panagora Asset Management's 13F filing for Q4 2020, filed 10 Feb 2021.